PreveCeutical Medical Inc.
PRVCF
$0.0235
$0.005429.83%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 82.13% | 430.27% | |||
| Depreciation & Amortization | 31.82% | 22.22% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 84.16% | 358.08% | |||
| Operating Income | -84.16% | -358.08% | |||
| Income Before Tax | -70.46% | -208.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -70.46% | -208.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -70.46% | -208.29% | |||
| EBIT | -84.16% | -358.08% | |||
| EBITDA | -84.41% | -364.65% | |||
| EPS Basic | -60.00% | -233.33% | |||
| Normalized Basic EPS | -66.67% | -200.00% | |||
| EPS Diluted | -60.00% | -233.33% | |||
| Normalized Diluted EPS | -66.67% | -200.00% | |||
| Average Basic Shares Outstanding | 4.79% | 0.00% | |||
| Average Diluted Shares Outstanding | 4.79% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||